Speciality Medicines Limited ipo

Speciality Medicines Limited is a fast-growing pharmaceutical company focused on manufacturing and marketing Finished Dosage Formulations (FDFs). They specialize in injectable and lyophilized vials, catering to niche therapeutic areas like anesthesia, critical care, and emergency medicine. Currently, they boast a portfolio of 28 products marketed across India, with plans to expand into regulated markets like the US. The company operates with a vertically integrated model, possessing a modern manufacturing facility approved by major regulatory bodies including the WHO-GMP and ISO. A significant portion of their revenue – around 78% in FY23 – comes from institutional sales, making them reliant on government tenders and hospital contracts. While this provides stability, it also introduces concentration risk. Financially, Speciality Medicines has demonstrated strong growth, with revenue increasing from ₹73.83 crore in FY21 to ₹189.62 crore in FY23. However, profitability remains a concern, with fluctuating net profit margins. The IPO proceeds will be used for capital expenditure, debt reduction, and working capital needs. Given the reliance on institutional sales and moderate profitability, investors should carefully consider these factors before investing